The Olympus Study

a phase 3, open-label, single-arm, multicenter trial in patients with treatment-naïve or recurrent low-grade UPPER TRACT UROTHELIAL CANCER with ≥ 1 measurable papillary tumor (N=71)1,2

Primary endpoint: Complete response (CR)1
Secondary endpoint: Durability of response at 12-month follow-up of CR evaluation2

  • CR was defined as a complete absence of tumor lesions in the ipsilateral pyelocalyceal system at 3 months after initiation of Jelmyto by urine cytology, ureteroscopy, and biopsy (if warranted)1
  • Patients with larger tumors could have had tumor debulking prior to treatment (37% underwent tumor debulking prior to enrollment)1
  • 100% of patients in the study received JELMYTO through retrograde instillation2
  • The dosage of Jelmyto was individualized based on volumetric measurements using pyelography with the intent to fill the renal pelvis (max dose was 15 mL or 60 mg mitomycin)1

Jelmyto was studied in patients typically seen in a clinical practice1,2

Patient Baseline Characteristics In The Olympus Study (N=71)
AgeMedian 71 yearsRange 42-87 years
Number of papillary tumorsMedian 1*Range 1-5
Diameter of largest papillary tumorMedian 8 mmRange 5-15 mm
Unresectable tumors at baseline48%
Prior history of low-grade UTUC52%

Both newly diagnosed patients (n=34) and patients with recurrent low-grade upper tract urothelial cancer (n=37) were included in the Olympus Study2

  • No data are available in patients with severe renal impairment. Avoid use of Jelmyto in patients with a glomerular filtration rate of < 30 mL/min1
Median number of papillary lesions subsequent to debulking, and prior to treatment, was 1 lesion (range 1-5).1

Featured resources

Download these resources to learn more and to get your appropriate patients started on Jelmyto treatment.

Jelmyto Treatment Algorithm


Scheduling and Ordering Resource


Jelmyto Patient Enrollment Form

Grid icon

Additional Resources

View More
See the clinical
results for both newly
diagnosed and
recurrent patients
support team icon

Contact a representative

Get more information about Jelmyto from a representative in your area.

Start here

Start patients on Jelmyto

Download the Patient Enrollment Form and order JELMYTO for your appropriate patients.

Download PDF
Full Prescribing InformationArrow (right) icon

Indications and Usage

Jelmyto® (mitomycin) for pyelocalyceal solution is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).

Important Safety Information


Jelmyto is contraindicated in patients with perforation of the bladder or upper urinary tract.

Ureteric Obstruction

Ureteric obstruction, including ureteral stenosis and hydronephrosis, occurred in patients receiving Jelmyto. Monitor patients for signs and symptoms of ureteric obstruction, including flank pain, and fever, and for changes in renal function. Patients who experience obstruction may require transient or long-term ureteral stents or alternative procedures. Withhold or permanently discontinue JELMYTO based on the severity of ureteric obstruction.

Bone Marrow Suppression

The use of Jelmyto can result in bone marrow suppression, particularly thrombocytopenia and neutropenia. The following tests should be obtained prior to each treatment: Platelet count, white blood cell count differential and hemoglobin. Withhold JELMYTO for Grade 2 thrombocytopenia or neutropenia. Permanently discontinue for Grade 3 or greater thrombocytopenia or neutropenia.

Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, Jelmyto can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of mitomycin resulted in teratogenicity. Advise females of reproductive potential to use effective contraception during treatment with JELMYTO and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with JELMYTO and for 3 months following the last dose.

Common Adverse Reactions

The most common adverse reactions in ≥ 20% of patients treated with Jelmyto were ureteric obstruction, flank pain, urinary tract infection, hematuria, abdominal pain, fatigue, renal dysfunction, nausea, dysuria, and vomiting.

Additional Adverse Reactions Information

Selected clinically relevant adverse reactions in < 10% and ≥ 2% of patients who received Jelmyto include urinary tract inflammation, bladder spasm, urosepsis, hypersensitivity, and instillation site pain.

Use in Specific Populations

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with Jelmyto and for 1 week following the last dose.

Preparation and Administration Information

Jelmyto is for pyelocalyceal use only and not for intravenous use, topical use, or oral administration. Jelmyto must be prepared and administered by a healthcare provider. To ensure proper dosing, it is important to follow the preparation instructions found in the JELMYTO Instructions for Pharmacy and administration instructions found in the JELMYTO Instructions for Administration.

Jelmyto may discolor urine to a violet to blue color following the instillation procedure. Advise patients to avoid contact with urine for at least six hours post-instillation, to void urine sitting on a toilet, and to flush the toilet several times after use.

Jelmyto is a hazardous drug. Follow applicable special handling and disposal procedures.

Please click here for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.

References: 1. JELMYTO [package insert]. Princeton, NJ: UroGen Pharma, Inc.; 2022. 2. Kleinmann N, Matin SF, Pierorazio PM, et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020;21(6):776-785.